For AYAs diagnosed with HR+/HER2+ breast cancer, prognosis varied by tumor grade, with the risk of breast cancer death higher in low-grade disease and lower in high-grade disease than AYAs diagnosed with HR+/HER2- breast cancer. This evidence concerns the gene ERBB2 and neoplasm.